Nmn (Nicotinamide Mononucleotide) for Cognitive Function

Research suggests that NMN may support cognitive function primarily through its role as a precursor to NAD+, a molecule that declines with age and is involved in cellular energy production, DNA repair, mitochondrial health, and protection of the blood-brain barrier. Studies indicate that restoring NAD+ levels through NMN supplementation has shown promise in preclinical models for reducing age-related blood-brain barrier deterioration, countering mitochondrial dysfunction relevant to Alzheimer's disease risk, and protecting neural tissue from oxidative and inflammatory damage. The available evidence draws heavily from reviews of animal and cell-based studies, with a smaller number of mechanistic investigations in human tissue, and the overall body of literature consistently notes that rigorous human clinical trials remain limited in number, sample size, and duration. While the directional findings across these studies are broadly supportive, researchers across multiple reviews emphasize that conclusions about whether NMN meaningfully improves cognitive outcomes in humans cannot yet be firmly drawn, and that well-designed clinical trials are needed before strong claims are warranted.